BioNexus Gene Lab Corp
NASDAQ:BGLC

Watchlist Manager
BioNexus Gene Lab Corp Logo
BioNexus Gene Lab Corp
NASDAQ:BGLC
Watchlist
Price: 4.11 USD -0.24% Market Closed
Market Cap: 7.4m USD

Intrinsic Value

The intrinsic value of one BGLC stock under the Base Case scenario is 4.43 USD. Compared to the current market price of 4.11 USD, BioNexus Gene Lab Corp is Undervalued by 7%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

BGLC Intrinsic Value
4.43 USD
Undervaluation 7%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
BioNexus Gene Lab Corp

What is Valuation History?
Ask AI Assistant
What other research platforms think about BGLC?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is BGLC valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for BioNexus Gene Lab Corp.

Explain Valuation
Compare BGLC to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about BGLC?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
BioNexus Gene Lab Corp

Current Assets 5.6m
Cash & Short-Term Investments 1.2m
Receivables 1.7m
Other Current Assets 2.7m
Non-Current Assets 2m
Long-Term Investments 237.8k
PP&E 1.8m
Other Non-Current Assets -100
Current Liabilities 678k
Accounts Payable 184.6k
Accrued Liabilities 56.8k
Other Current Liabilities 436.6k
Non-Current Liabilities 127k
Other Non-Current Liabilities 127k
Efficiency

Free Cash Flow Analysis
BioNexus Gene Lab Corp

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
BioNexus Gene Lab Corp

Revenue
9.5m USD
Cost of Revenue
-8.1m USD
Gross Profit
1.4m USD
Operating Expenses
-3.8m USD
Operating Income
-2.4m USD
Other Expenses
72k USD
Net Income
-2.3m USD
Fundamental Scores

BGLC Profitability Score
Profitability Due Diligence

BioNexus Gene Lab Corp's profitability score is 13/100. The higher the profitability score, the more profitable the company is.

Healthy Gross Margin
Gross Margin is Increasing
Sustainable 3Y Average Gross Margin
Declining Net Margin
13/100
Profitability
Score

BioNexus Gene Lab Corp's profitability score is 13/100. The higher the profitability score, the more profitable the company is.

BGLC Solvency Score
Solvency Due Diligence

BioNexus Gene Lab Corp's solvency score is 93/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
93/100
Solvency
Score

BioNexus Gene Lab Corp's solvency score is 93/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BGLC Price Targets Summary
BioNexus Gene Lab Corp

There are no price targets for BGLC.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

BioNexus Gene Lab Corp
does not pay dividends
Shareholder Yield

Current shareholder yield for BGLC is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one BGLC stock?

The intrinsic value of one BGLC stock under the Base Case scenario is 4.43 USD.

Is BGLC stock undervalued or overvalued?

Compared to the current market price of 4.11 USD, BioNexus Gene Lab Corp is Undervalued by 7%.

Back to Top